2. (Human P
apilloma Virus (HP
V
Double-stranded DNA viruses.
Papillomaviruses.
Sexual transmission
Non
-sexual
transmission
(autoinoculation)
IP averages 3 to 4 months, with a
range from 1 month 2 years.
12. Diagnosis
Clinical picture
Acetic acid 3-5%: (false +ve, false –ve)
Pap smear
HPV typing
Consider biopsy if:
Diagnosis is uncertain
Lesions are unresponsive to or worsen during therapy
Warts are pigmented, indurated, fixed, or ulcerated
Individual warts are larger than 1 cm
14. Pap Smear for Cervical
(Intraepithelial Neoplasia (CIN
15. Pap Smear for Cervical
(Intraepithelial Neoplasia (CIN
16. Subclinical Genital HPV Infection
(Without Exophytic Warts)
(Condyloma P
lana)
Manifestations of infection in the absence of
genital warts.
Infection is detected on the cervix by Pap test,
or biopsy.
Appearance of white areas after application of
acetic acid.
19. Dif f erential Diagnosis
• Dome-shaped
or
hairlike projections on
the corona or shaft
adjacent to the corona
on 10% of male
patients. Normal.
Pearly White Papules
20. Dif f erential Diagnosis
Shining, pearly white umbilicated papules
A semisolid white material can be
. expressed from the central umbilication
Molluscum Contagiosum
21. Dif f erential Diagnosis
On
less keratinized
surfaces: tend to be
broader based, flatter
topped, and less friable
than warts.
On keratinized skin: the
papules are copper
colored and surmounted
by scale.
Inguinal adenopathy is
often present .
Condyloma Lata
22. Dif f erential Diagnosis
Multiple papules with
smooth or verrucous
surface
Usually pigmented
HPV 16 presents in
most cases
Bowenoid Papulosis
23. Rec om ended Regi m
m
ens f or
Ext er nal Geni t al W t s
ar
• Patient-Applied:
• Podofilox 0.5% solution or gel:
Antimitotic drug that destroys wart
Twice a day for 3 days, followed by 4 days of no therapy/
four cycles.
The total wart area treated should not exceed 10 cm2/
podofilox limited to 0.5 mL per day.
Most patients experience mild/moderate pain or local
irritation after treatment.
24. Rec om ended Regi m
m
ens f or
Ext er nal Geni t al W t s
ar
Imiquimod 5% cream:
Topically active immune enhancer that stimulates
production of interferon and other cytokines
Three times a week for up to 16 weeks.
The treatment area should be washed with soap and
water 6--10 hours after the application.
Moderate erythema, erosions and tenderness.
25. Rec om ended Regi m
m
ens f or
Ext er nal Geni t al W t s
ar
• Provider-Administered:
Cryotherapy with liquid nitrogen or cryoprobe.
• Causes epidermal necrosis
• Repeat applications every 1--2 weeks.
26. Rec om ended Regi m
m
ens f or
Ext er nal Geni t al W t s
ar
Podophyllin resin 10%-25% in a compound tincture
of benzoin:
Cytotoxic, antimitotic
A small amount should be applied to each wart and
allowed to air dry.
The treatment can be repeated weekly, if necessary.
To avoid the possibility of complications application
be limited to <0.5 mL or an area of <10 cm2 of warts per
session.
The preparation should be thoroughly washed off 1-4
hours after application to reduce local irritation.
27. R
ecommended R
egimens f or
External Genital Warts
• Trichloroacetic acid (TCA) 80%--90%.
Destroy warts by chemical coagulation of the protein
A small amount should be applied only to warts and
allowed to dry white "frosting" develops.
The treated area should washed by sodium bicarbonate to
remove unreacted acid.
This treatment can be repeated weekly, if necessary.
Intense burning sensation, ulceration.
28. R
ecommended R
egimens f or
External Genital Warts
Surgical removal
Electrocautery.
Care must be taken to control the depth of
electrocautery to prevent scarring.
Tangential excision with a pair of fine
scissors or a scalpel or by curettage.
Carbon dioxide LASER
29. Factors that may inf luence
selection of treatment
Wart size
Wart number
Anatomic site of wart
Wart morphology
Patient preference
Cost of treatment
Adverse effects
Provider experience
32. Treatment Of Subclinical
Inf ection
The diagnosis of subclinical genital HPV infection is
often not definitive, and no therapy has been
identified that eradicates infection.
In the absence of coexistent SIL, treatment is not
recommended for subclinical genital HPV
In the presence of coexistent SIL, management should
be based on histopathologic findings.
33. Pr egnancy
The physiologically impaired immune status of the
mother enhances the grow of genital warts.
The choice of therapy must not endanger the fetus.
Do not use imiquimod, podophyllin, or podofilox in
pregnant women because of potential risk to the fetus.
Physician-applied topical treatment with TCA,
freezing with liquid nitrogen, or electrocautery
34. Patient Education: General Information
Reassure the patient that HPV is a common viral
infection and that is not a result of poor hygiene.
Inform the patient that warts may disappear by
themselves or may recur after treatment.
Explain that HPV infection may or may not persist
Explain that the goal of treatment is to get rid of the
warts, not to eliminate the HPV infection.
35. Discuss and explain available treatments: Explain
each treatment and its limitations and side effects.
Explain that healing after wart treatment takes time,
and that abstinence or condom use are needed until
the area is completely healed.
Explain that the patient sexual partner is almost
certainly infected with HPV (and may even have
transmitted it to the patient).
36. Stress the importance of female patients and female
sexual partners having regular Pap smears because
HPV can cause cervical cancer.
Explain to the patient and his or her sexual partner
that genital warts do not necessarily imply infidelity,
because it is usually not possible to determine when
the virus was initially acquired.
